Jobs
-
Bryn Pharma announced the publication of a poster presenting data from a Phase 1 PK/PD study of its BRYN-NDS1C intranasal epinephrine, which is delivered via an Aptar Pharma Bidose nasal device. In October 2019, Bryn… Read more . . .
-
Savara announced that it has acquired global development and commercialization rights to Apulmiq (Linhaliq) inhaled liposomal ciprofloxacin from Grifols. According to Savara, the deal includes an upfront payment to Grifols and regulatory milestone payments if… Read more . . .
-
The University of Wisconsin–Madison has announced that virologists from the university have partnered with vaccine companies FluGen and Bharat Biotech on development of an intranasal vaccine against unique vaccine against SARS-CoV-2 for the prevention of… Read more . . .
-
Swiss biotech Neurimmune has partnered with German mRNA specialist Ethris to develop inhaled mRNA-encoded neutralizing anti-SARS-CoV-2 antibodies for the treatment of Covid-19, the companies said. The goal is to begin clinical manufacturing of the drug… Read more . . .
-
Austrian biotech APEPTICO said that it has signed a grant agreement with the European Commission to accelerate the availability of the company’s solnatide (AP301), an inhaled peptide, available for treatment of patients with severe COVID-19. APEPTICO… Read more . . .
-
A number of Cambridge, UK-based companies with extensive experience in inhaler design and development have responded to a request from the UK government to join an initiative to rapidly increase the country’s manufacture of ventilators in… Read more . . .
-
At a March 27, 2020 meeting of the EMA’s Committee for Medicinal Products for Human Use (CHMP), the committee adopted a positive opinion regarding the MAAs for Novartis’s Atectura Breezhaler indacaterol/mometasone furoate and a duplicate… Read more . . .
-
Altimmune has announced a collaboration with the University of Alabama at Birmingham (UAB) for development of an intranasal COVID-19 vaccine. Six laboratories at UAB are expected to work on the single dose vaccine, called AdCOVID, to complete… Read more . . .
-
Verona Pharma has announced that a Phase 2 trial of 5 dosage strengths of an MDI formulation of ensifentrine for the treatment of moderate to severe COPD demonstrated that all but the lowest dose of… Read more . . .
-
Windtree Therapeutics has announced that Lee’s Pharmaceutical Holdings will provide funding for a Phase 2b study of Windtree’s Aerosurf inhaled KL4 surfactant for the treatment of respiratory distress syndrome in preterm infants. Windtree will repay… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.